# Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout

> **NCT00663169** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 6 (actual)

## Conditions studied

- Arthritis, Gouty

## Interventions

- **BIOLOGICAL:** canakinumab
- **DRUG:** dexamethasone
- **OTHER:** placebo matching canakinumab
- **OTHER:** placebo matching dexamethasone

## Key facts

- **NCT ID:** NCT00663169
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2013-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00663169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00663169, "Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00663169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*